LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Zai Lab Ltd ADR

Затворен

СекторЗдравеопазване

34.66 -4.17

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

34.44

Максимум

36.1

Ключови измерители

By Trading Economics

Приходи

33M

-48M

Продажби

-2.6M

106M

EPS

-0.45

Марж на печалбата

-45.487

Служители

1,869

EBITDA

19M

-56M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+46.56% upside

Дивиденти

By Dow Jones

Следващи печалби

5.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

777M

4.2B

Предишно отваряне

38.83

Предишно затваряне

34.66

Настроения в новините

By Acuity

50%

50%

162 / 380 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Zai Lab Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.06.2025 г., 20:51 ч. UTC

Печалби

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

27.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

27.06.2025 г., 20:48 ч. UTC

Пазарно говорене

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27.06.2025 г., 20:46 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

27.06.2025 г., 20:46 ч. UTC

Пазарно говорене

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27.06.2025 г., 19:31 ч. UTC

Пазарно говорене

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27.06.2025 г., 19:19 ч. UTC

Пазарно говорене

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27.06.2025 г., 19:16 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27.06.2025 г., 18:42 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.06.2025 г., 18:42 ч. UTC

Пазарно говорене

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27.06.2025 г., 18:39 ч. UTC

Пазарно говорене
Печалби

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27.06.2025 г., 18:29 ч. UTC

Пазарно говорене

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27.06.2025 г., 18:18 ч. UTC

Пазарно говорене

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27.06.2025 г., 18:16 ч. UTC

Пазарно говорене

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27.06.2025 г., 17:16 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27.06.2025 г., 17:08 ч. UTC

Печалби

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27.06.2025 г., 16:52 ч. UTC

Придобивния, сливания и поглъщания

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27.06.2025 г., 16:22 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

27.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

27.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

27.06.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

27.06.2025 г., 15:59 ч. UTC

Пазарно говорене

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27.06.2025 г., 15:56 ч. UTC

Пазарно говорене

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Zai Lab Ltd ADR Прогноза

Ценова цел

By TipRanks

46.56% нагоре

12-месечна прогноза

Среден 53.04 USD  46.56%

Висок 66 USD

Нисък 38.2 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Zai Lab Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

6

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

28.13 / 31.12Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

162 / 380 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.